Revolutionary Stem Cell Treatment fot Autism Will Help Your Child http://tinyurl.com/st0pagingn0w - Your child has been diagnosed with Autism? Stem cell therapy is an innovative and successful approach to treating autism, a... By: cellularrejuvenation … Continue reading →

Nichole Dobo, The (Wilmington, Del.) News Journal 11:41 a.m. EST February 5, 2014 Dr. Nancy Brady at Animal Haven Veterinary Center takes blood from Grover, a 4 year-old German Shepherd, while he is held by vet technician Savannah Haines, before they harvested fat tissue for a stem cell replacement procedure on Tuesday, Feb. 4, 2014.(Photo: Jennifer Corbett, The Wilmington, Del., News Journal) Grover loves to play fetch. But five months ago, while chasing a ball outside, the 4-year-old German shepherd blew out one of his back knees. He showed up with a limp at Animal Haven Veterinary Center in Bear, where he received treatment that helped, but he still had pain. His owner, John Przybyliski, wanted a better outcome for his best friend. So, on Tuesday, Dr. Nancy Brady infused Grover's joint with stem cells she had extracted from his own fat tissue earlier in the day the first such procedure in Delaware to use an in-house stem cell treatment developed by a Kentucky-based company called MediVet America. The cost: $2,249. "It is financially a burden to us, because I am retired, but if this will help him, it will be worth every penny," said Przybyliski, who lives near New … Continue reading →

Miami (PRWEB) February 05, 2014 Global Stem Cells Group, Inc. and BioHeart, Inc. announce the launch of a clinical trial for the treatment of Chronic Obstructive Pulmonary Disease (COPD) using adipose-derived stem cell technology. The clinical trials will be held at the Global Stem Cells treatment center in Cozumel, Mexico, as well as in several U.S. states. Global Stem Cells Group affiliate Regenestem in collaboration with CMC Hospital of Cozumel offer cutting-edge cellular medicine treatments to patients from around the world The study titled "An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered intravenously in Patients with Chronic Obstructive Pulmonary Disease" is lead by principal investigator Armando Pineda Velez, Global Stem Cells Group Medical Director. Global Stem Cells Group has represented that it offers the most advanced protocols and techniques in cellular medicine from around the world. The Cozumel clinical trials will be lead by Rafael Moguel, M.D., an advocate and pioneer in the use of stem cell therapies to treat a wide variety of conditions. COPD is one of more than 150 chronic conditions that are treatable with adult stem cells, eliminating the potential risk of surgery, transplants, and toxic drugs … Continue reading →

A new study, published today in the journal Applied Materials & Interfaces, has found a new method for growing human embryonic stem cells, that doesn't rely on supporting human or animal cells. Traditionally, these stem cells are cultivated with the help of proteins from animals, which rules out use in the treatment of humans. Growing stem cells on other human cells risks contamination with pathogens that could transmit diseases to patients. The team of scientists led by the University of Surrey and in collaboration with Professor Peter Donovan at the University of California have developed a scaffold of carbon nanotubes upon which human stem cells can be grown into a variety of tissues. These new building blocks mimic the surface of the body's natural support cells and act as scaffolding for stem cells to grow on. Cells that have previously relied on external living cells can now be grown safely in the laboratory, paving the way for revolutionary steps in replacing tissue after injury or disease. Dr Alan Dalton, senior lecturer from the Department of Physics at the University of Surrey said: "While carbon nanotubes have been used in the field of biomedicine for some time, their use in human … Continue reading →

HATFIELD, England, February 3, 2014 /PRNewswire/ -- Eisai announces today that Zebinix (eslicarbazepine acetate), a novel anti-epilepsy treatment, has received full reimbursement from the Finnish Health Authorities. Once-daily eslicarbazepine acetate, is indicated as adjunctive therapy in adults with partial onset seizures, with or without secondary generalisation.[1] "Up to a third of people with epilepsy do not achieve adequate seizure control after their first anti-epileptic treatment so there is a continued need for additional effective options. Eslicarbazepine acetate will provide doctors with a new, easy to titrate, adjunctive therapy to help those with inadequately controlled partial onset epilepsy improve their condition," commented Dr. Jukka Peltola, Tampere University Hospital. Epilepsy is one of the most common neurological conditions in the world and affects approximately 56,000 people in Finland.[2],[3]Despite many anti-epileptic drugs (AEDs) available, the successful treatment of partial onset seizures remains a significant challenge in some patients. Currently, between 20-40% of patients with newly diagnosed epilepsy will become refractory to treatment.[4] Eslicarbazepine acetate, a third generation sodium channel blocker that differentially and selectively targets slow inactivated sodium channels, was approved by the European Commission in 2009 based on data submitted which showed that it reduces seizure frequency by up to 45% in … Continue reading →

PUBLIC RELEASE DATE: 6-Feb-2014 Contact: Dawn Peters sciencenewsroom@wiley.com 781-388-8408 Wiley New research shows that children with febrile status epilepticus (FSE) who receive earlier treatment with antiepileptic drugs (AEDs) experience a reduction in the duration of the seizure. The study published in Epilepsia, a journal of the International League Against Epilepsy (ILAE), suggests that a standard Emergency Medical Services (EMS) treatment protocol for FSE is needed in the U.S. While medical evidence reports that brief or simple febrile seizures are most common, up to 10% of cases are prolonged and meet the criteria for status epilepticus (SE)a critical condition where a persistent seizure lasts more than 30 minutes. Prior research shows that FSE accounts for 25% of all childhood SE, with more than 70% of SE cases occurring in the second year of life. Prolonged seizures place patients at risk of short-term and long-term complications, including the development of epilepsy. "The time from the start of the seizure to treatment is crucial to improving patient outcomes," said lead author Syndi Seinfeld, DO, assistant professor, Division of Child Neurology at Children's Hospital of Richmond at Virginia Commonwealth University. "Our study is the first to examine the treatment of FSE by EMS, which … Continue reading →